O-1269
O-1269 is a synthetic compound of the cannabinoid family. It is a selective agonist for the CB1 receptor, and was developed for medical use by Organix Inc.
Chemistry[edit | edit source]
O-1269 is a member of the cannabinoid family of compounds, which also includes natural products from the cannabis plant as well as synthetic analogues. It is a selective agonist for the CB1 receptor, meaning it binds to this receptor and activates it.
Pharmacology[edit | edit source]
The CB1 receptor is one of two main cannabinoid receptors in the body, the other being the CB2 receptor. These receptors are part of the endocannabinoid system, which plays a role in a variety of physiological processes including pain sensation, mood, and memory. As a selective CB1 agonist, O-1269 has the potential to influence these processes.
Medical Use[edit | edit source]
O-1269 was developed for medical use by Organix Inc., a pharmaceutical company specializing in the development of cannabinoid-based therapies. However, as of now, it is not approved for use in any country.
See Also[edit | edit source]
O-1269 Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD